| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2276405ae0e23cfcd15651de21c8565 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 |
| filingDate |
2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d47a7e296ff68c00aa866faa0f78311c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc36ae4efe0bc50dcaba379b8cd8bde8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0a41644d2ff05be8eb320119c2d58c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1985a2397905ed52002777477c55ff37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_834d30ab5b3eb4e4d8846bc2bbb6c869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a27bc03127e95dc66c94601fb5c34e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_498bb719f18b1e114704cac720a6dcd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0757c7f2ab1c575daa90d07302a9c38b |
| publicationDate |
2017-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2621208-T3 |
| titleOfInvention |
Methods for purifying erythropoietin analogs that have lower isoelectric point |
| abstract |
A method for purifying an erythropoietin analogue (EPO) that has an isoelectric point below 4, which is a new erythropoiesis stimulating protein (NESP) that has five N-linked sugar chains comprising: (a) Obtaining a solution pretreated by removing animal cells from a culture solution of animal cells, wherein animal cells express the erythropoietin analog having an isoelectric point below 4; (b) Obtain a first fraction comprising the erythropoietin analog by subjecting the pretreated solution to a first anion exchange chromatography, where a pH regulator below 4.0 is used as a wash regulator in the first anion exchange chromatography ; (c) Obtain a second fraction comprising the erythropoietin analog by subjecting the first fraction to hydroxyapatite chromatography; and (d) Obtaining a third fraction comprising the erythropoietin analog by subjecting the second fraction to a second anion exchange chromatography, in which a pH regulator 2.0-4.0 is used as a wash regulator in the second chromatography of anion exchange. |
| priorityDate |
2011-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |